Cirrhosis News and Research

Latest Cirrhosis News and Research

Paracentesis performed in an outpatient setting by gastrointestinal endoscopy assistants is safe

Large-volume paracentesis is a treatment used to remove excess fluid in the abdominal cavity resulting from such conditions as cirrhosis of the liver or cardiac failure. It is normally performed as an inpatient procedure due to possible complications, which may include infection, bleeding, and bowel perforation.

18 Aug 2004

Binge drinking accounts for a substantial number of deaths each year in the United States

Binge drinking and harmful drinking, including both medium to high levels of regular alcohol consumption, account for a substantial number of deaths each year in the United States.

9 Aug 2004

Self-recovery from Hep C infection linked to genes that suppress action of killer immune cells

In a study to be published in Science online Aug. 6, researchers at Johns Hopkins have found that genes involved in suppressing the body's defensive "killer" immune cells are a potential key factor in spontaneous recovery from hepatitis C.

5 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

Researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS

Sydney University medical researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS in the latest round of National Health and Medical Research Council program grants.

2 Aug 2004

Researchers found that a significant number of men get the hepatitis B virus behind bars

In the first study to gauge the risks of contracting HIV and hepatitis in Rhode Island prisons, Brown University researchers found that a significant number of men get the hepatitis B virus behind bars – a finding that led the team to call for prison-wide vaccinations. Results are published in the current edition of the American Journal of Public Health.

7 Jul 2004

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

Viruses’ growing resistance to drugs means diseases such as hepatitis B and C are increasingly difficult to treat. New pandemics may arise with unforeseeable consequences.

29 Jun 2004

Breakthrough in gene therapy

Despite a roller-coaster ride of ups and downs during the past 15 years, gene therapy has continued to attract many of the world's brightest scientists. They are tantalized by the enormous potential that replacing missing genes or disabling defective ones offers for curing diseases of many kinds.

3 Jun 2004

Bone marrow stem cells exposed to damaged liver tissue quickly convert into healthy liver cells

Bone marrow stem cells, when exposed to damaged liver tissue, can quickly convert into healthy liver cells and help repair the damaged organ, according to new research from the Johns Hopkins Kimmel Cancer Center.

2 Jun 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Anemia is a major determinant of fatigue in patients with cirrhosis

Fatigue is a common complaint among patients with cirrhosis with many possible contributing factors, including severity of liver disease, anemia, and cardiopulmonary complications.

27 May 2004

Causes of hepatitis and potential therapies that may improve care presented in study

Hepatitis, a potentially serious disease caused by a virus that attacks the liver, is a major problem worldwide. Hepatitis A is generally food-borne, while hepatitis B and C spread primarily through parenteral or sexual routes. Hepatitis B and C can be life-long, potentially deadly chronic infections.

19 May 2004

Fatty liver disease (NAFLD) in obese children has distinct characteristics different from those found in adults

Potentially life-threatening non-alcoholic fatty liver disease (NAFLD) in obese children has distinct characteristics, often different from those found in adults, according to a University of California, San Diego (UCSD) School of Medicine study led by Jeffrey Schwimmer, M.D., assistant professor of pediatrics.

19 May 2004

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.

18 May 2004

Signs of liver disease also improve in conjunction with alterations to gut flora

Some cirrhotic patients develop brain dysfunction, called hepatic encephalopathy, which causes deficits in behavior, intelligence, consciousness and neuromuscular function.

14 May 2004

Screening for liver diseases benefits outweigh costs for some, but not all, conditions

Screening programs for liver diseases can detect asymptomatic conditions which might have better outcomes if diagnosed and treated earlier.

14 May 2004

Hepatitis B vaccination for inmates

rrectional settings provide a unique opportunity to offer hepatitis B vaccination to a substantial number of high-risk adults who are willing to be vaccinated and who would not otherwise have access to the preventive medicine, according to a new Brown University study of inmates within the Rhode Island Department of Corrections.

23 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Cirrhosis News and Research

Latest Cirrhosis News and Research

Paracentesis performed in an outpatient setting by gastrointestinal endoscopy assistants is safe

Binge drinking accounts for a substantial number of deaths each year in the United States

Self-recovery from Hep C infection linked to genes that suppress action of killer immune cells

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Researchers have secured more than $19.4 million for their work on cardiovascular and liver diseases and HIV/AIDS

Researchers found that a significant number of men get the hepatitis B virus behind bars

The EU is contributing €9 million to the “Vigilance against Viral Resistance” (VIRGIL) project

Breakthrough in gene therapy

Bone marrow stem cells exposed to damaged liver tissue quickly convert into healthy liver cells

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Anemia is a major determinant of fatigue in patients with cirrhosis

Causes of hepatitis and potential therapies that may improve care presented in study

Fatty liver disease (NAFLD) in obese children has distinct characteristics different from those found in adults

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Signs of liver disease also improve in conjunction with alterations to gut flora

Screening for liver diseases benefits outweigh costs for some, but not all, conditions

Hepatitis B vaccination for inmates

Schering-Plough submits Japanese application for hepatitis C drug

Preclinical data on Histamine's ability to prevent liver damage

Hepatitis C wonder drug Ribasphere gets approval from FDA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Cirrhosis News and Research

Latest Cirrhosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in